Trader Joe's issued a recall on one of its healthier items. It may contain plastic
Have an organic acai bowl from Trader Joe's in your refrigerator?
Before you use its mix of wild berries, bananas, dried coconut and granola in your next smoothie opt for something else from Trader Joe's or your other favorite fruit blend.
What's the problem?
The California-based company has urged its customers to discard or return the Trader Joe's Organic Acai Bowl to the store for a refund because the mix may include stray pieces of plastic inside the package.
The acai bowl recall was not initiated by the USDA or FDA as many recalls are but rather by Trader Joe's on Feb. 14 with a brief explanation. 'Out of an abundance of caution,' the short notice read.
Trader Joe's did not say how the problem occurred in the manufacturing process but did note that the suspected foreign material was plastic.
What you should do
The announcement added that customers with questions can call Trader Joe's Customer Relations at 626-599-3817 or send the company an email via a link to its product feedback page.
Acai's dark purple berries are from a palm tree found throughout South America and are touted as an antioxidant-rich food source that some nutritionists believe can protect cells from damage, according to WebMD. Proponents say the berries are richer in antioxidants than cranberry, raspberry, blackberry, strawberry or blueberries.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
40 minutes ago
- USA Today
How long does a cold last? And how long are you contagious?
Many people think of December and January as the two months of the year you're likely to catch the common cold, but 'cold season' actually stretches from late August through April. That means only about three months of the year, typically May through July, fall outside it. But even during these 'off' months, nearly one in 10 people still catch a cold, according to data from the U.S. Centers for Disease Control and Prevention. In other words, in any given month, tens of millions of people are walking around with telltale cold symptoms like a stuffy nose, headache, fatigue, sneezing, sore throat and sometimes a cough or low-grade fever. Here's what causes colds to spread so easily, how long they are usually contagious and how they're most commonly treated. What are the main causes of a cold? The common cold is most often caused by a viral infection. Rhinoviruses are the leading culprit, but other viruses such as adenoviruses, certain coronaviruses, respiratory syncytial virus (RSV) and parainfluenza viruses can also trigger cold symptoms by infecting the upper respiratory tract. Need a break? Play the USA TODAY Daily Crossword Puzzle. These and more than 200 other viruses spread through saliva or mucus particles expelled from a sick person. 'To catch a cold, you must introduce a cold virus from someone else into your airway,' says Dr. David Hill, a North Carolina-based pediatrician and spokesperson for the American Academy of Pediatrics. This typically happens when infected respiratory droplets are released into the air when a sick person talks, sings, sneezes or coughs. In addition to being inhaled directly, viruses can also land on surfaces and spread when someone touches a contaminated surface and then brushes their nose, eyes or mouth. 'Being in shared spaces often increases the likelihood of transmission,' says Dr. Alison Mitzner, a New York City-based board-certified pediatrician and author of "Calm and Confident Parenting." Other risk factors include a weakened immune system, preexisting health conditions, exposure to cigarette smoke, colder months with lower humidity (which dry out nasal passages) and aging. "Sleep deprivation and fatigue can also make people more susceptible to catching a cold," adds Hill. How long are colds contagious? One of the reasons colds spread so frequently is that they are contagious even before symptoms begin, often one or two days beforehand. After that, "you're usually contagious for as long as you have symptoms, which typically last seven to ten days," says Mitzner. While germs can spread anytime throughout this period, the most viral shedding tends to happen around days four to six. "Know that you can remain contagious for up to two weeks though," she adds. Hill says it's also important to note that "different cold viruses have different levels of contagion." RSV, for example, "is extraordinarily easy to transmit at it can survive on surfaces for hours," he explains. Yes, pneumonia can be contagious. But here's why it depends on the form. How are colds treated? While symptoms can almost always be managed, 'there are no treatments that shorten the duration of a cold,' says Hill. Instead, "every cold just needs to run its course," says Mitzner. To relieve symptoms in the meantime, Hill recommends saltwater nasal rinses for congestion or using nasal decongestants like oxymetazoline if symptoms are especially bad. But he cautions against using them for more than two to three days due to the risk of rebound congestion which, he says, "may be worse than the cold itself." Medications such as acetaminophen or ibuprofen can also reduce fever and alleviate sore throat or headaches but should not be given to very young children without medical advice. For younger kids, Hill recommends honey as a natural cough and sore throat remedy, though he emphasizes that infants and kids under 1 year should never be given honey due to the risk of botulism. 'When you catch a cold, it's important to let your body heal,' says Mitzner. That means rest, hydration and the use of 'a cool-mist humidifier at night to breathe easier.'
Yahoo
2 hours ago
- Yahoo
‘Game-changer' new blood test to detect prevalent autoimmune disease without nightmare side effects
People with coeliac disease may soon be able to avoid consuming large quantities of gluten – the substance that triggers their symptoms – to get a diagnosis. New clinical research published in the journal Gastroenterology has shown a 'game-changer' blood test for gluten-specific T cells that can detect coeliac disease – even when no gluten has been consumed. Currently, people with suspected coeliac are required to eat large amounts of gluten for weeks to get an accurate diagnosis. However, researchers said the new blood test could boost rates of diagnosis, identify patients at risk of severe reactions to gluten and detect silent coeliac disease in asymptomatic people. Coeliac disease is an autoimmune condition where the body attacks its own tissues when gluten is eaten, which prevents normal digestion and absorption of food, with the risk of developing serious health complications. It is driven by eating gluten, a protein found in wheat, barley and rye. An estimated 1 in 100 people have it in the UK. However, only 36 per cent with the condition are clinically diagnosed, according to Coeliac UK. Undiagnosed or untreated coeliac disease can result in complications such as osteoporosis, unexplained infertility, neurological dysfunction and, in rare instances, small bowel cancer, Coeliac UK says. Currently, all coeliac testing methods require regular gluten consumption to be effective, the researchers said. Many people are deterred from seeking a definite diagnosis because they do not want to consume gluten and be sick, the Australia-based scientists added. Associate Professor Jason Tye-Din, Head of WEHI's Coeliac Research Laboratory and a gastroenterologist at the Royal Melbourne Hospital, said: 'There are likely millions of people around the world living with undiagnosed coeliac disease simply because the path to diagnosis is difficult, and at times, debilitating.' 'By eliminating the need for a gluten challenge, we're addressing one of the biggest deterrents in current diagnostic practices,' she added. 'This test could be a game-changer, sparing thousands of people the emotional and physical toll of returning to gluten. It's a major step towards faster, safer diagnosis.' The study evaluated the potential of a blood test to measure an immune marker interleukin 2 (IL-2). In 2019, researchers found this immune marker spiked in the bloodstream of people with coeliac disease shortly after they ate gluten. The scientists used blood samples from 181 volunteers, including 75 people with treated coeliac disease, 13 with active, untreated coeliac disease, 32 people with non-coeliac gluten sensitivity and 61 healthy people. Participant blood samples were then mixed with gluten in a test tube for a day to see if the IL-2 signal appeared. The team was 'thrilled' to find the test could detect the condition with up to 90 per cent sensitivity and 97 per cent specificity – even in patients following a strict gluten-free diet, PhD researcher Olivia Moscatelli, who was diagnosed with coeliac disease at 18, said. The IL-2 signal only increased in the volunteers with coeliac disease, showing the immune response to gluten can be detected in a tube, without the need to consume gluten, researchers said. Ms Moscatelli said the test also performed exceptionally well in people with coeliac disease who had other autoimmune conditions, such as type 1 diabetes or Hashimoto's thyroiditis. The Walter and Eliza Hall Institute team are now collaborating with Novoviah Pharmaceuticals to confirm the test's accuracy across diverse populations and find real-world data.
Yahoo
2 hours ago
- Yahoo
Outcomes4Me Acquires Germany's Mika Health App to Accelerate AI-Driven Patient Empowerment Globally
Mika's cancer app is a certified medical device clinically proven to help cancer patients cope with both the physical and psychological effects of their diagnosis BOSTON and BERLIN, June 12, 2025 /PRNewswire/ -- Outcomes4Me Inc., the developer of the leading, direct-to-patient, AI-driven platform transforming the cancer-care experience, announced today that its German affiliate Outcomes4Me Germany GmbH has acquired the assets associated with the Mika Health app from Berlin-based Fosanis GmbH. The Mika app has served over 100,000 cancer patients globally, and is a clinically validated platform proven in clinical trials to reduce a range of symptoms associated with cancer care including depression, anxiety, and fatigue. Outcomes4Me, which supports more than 280,000 cancer patients, recently finalized a $21M funding round, emphasizing the company's plans to expand both its patient community and commercial business globally. This acquisition strengthens Outcomes4Me's platform with Mika's proven interventions for real-time symptom management, behavioral coaching, and emotional support, setting a new global standard for digital oncology support. It also allows Outcomes4Me to scale faster in European markets, leveraging Mika's regulatory readiness as MDR IIa-certified medical device and local partnerships. "With this acquisition, we're taking a major step toward our mission to make cancer understandable and manageable to every patient wherever and whomever they are," said Maya Sc.D., Founder and CEO of Outcomes4Me. "Mika's proven AI-driven emotional support technology and European footprint complement our evidence-based platform grounded in clinical guidelines and U.S. footprint. Together, we're building the most comprehensive digital companion for cancer patients worldwide." "Joining forces with Outcomes4Me allows us to take our vision further, faster," said Gandolf Finke, Ph.D., Founder and Managing Director of Fosanis GmbH. "We're excited to integrate our technology with a partner that shares our values of transparency, trust, and patient empowerment. The overlap in our customer base of global pharmaceutical companies that prioritize innovation and whole-patient care creates many synergies and allows us to immediately deliver combined value for our patients and business partners alike. For our patients using Mika, this transaction has no impact in terms of service they can expect." Outcomes4Me will exhibit at HLTH Europe in Amsterdam from June 16-19, 2025. Visit Outcomes4Me and Mika in the AI Spotlight pavilion at booth #F70-2. About Outcomes4MeOutcomes4Me is the first and leading end-to-end, AI-driven patient empowerment platform that helps patients with cancer take a proactive approach to their care from diagnosis throughout every stage of life and care. Its direct-to-patient platform integrates clinical guidelines, genomics, trial matching, and symptom tracking to help patients navigate through a cancer diagnosis with confidence and clarity. Through its patented technology, Outcomes4Me is redefining cancer care by delivering smarter, AI-powered solutions that put patients in control of their treatment decisions. What sets Outcomes4Me apart is its ability to generate unique, at-scale proprietary datasets that enable more precise and actionable insights for better patient outcomes. Based in Boston, Massachusetts, Outcomes4Me is a woman-led company of seasoned healthcare, oncology, pharmaceutical, consumer and technology veterans. For more information, visit About Mika HealthMika Health is an app-based platform aimed at providing targeted and comprehensive support to people with cancer using digital technology. Through scientifically proven methods and techniques of therapy management, the Digital Therapeutics (DTx) helps patients to actively participate in their treatment and regain more quality of life - with daily symptom monitoring, psychologically oriented coaching courses, and AI-supported, personalized recommendations. To achieve this, Mika combines innovative machine learning technologies with a multimedia knowledge database of rigorously verified content, such as nutritional tips, exercise routines, or mindfulness training. For more information, visit View original content: SOURCE Outcomes4Me Inc.
